A New Cancer Program Partnership
On July 1 2013, North Kansas City Hospital and The University of Kansas Cancer Center launched a collaborative effort to create a new cancer program at North Kansas City Hospital. The partnership operates the radiation oncology program at the Hospital with physician staffing provided by The University of Kansas Cancer Center. Watch the video announcement.
Radiation + Medical Oncology
Beginning in the fall and led by longtime Northland providers Bob Pluenneke, MD, and Chris Sirridge, MD, The University of Kansas Cancer Center will also operate and staff a medical oncology program. The adjacent spaces located at 2750 Clay Edwards Drive on the Hospital’s campus will maximize the multidisciplinary approach to cancer diagnosis and treatment.
Expanding Patient Care
“This partnership is a way to expand our existing cancer program with a program that shares our focus on the quality of patient care,” says North Kansas City Hospital President and CEO Peggy Schmitt. “This collaborative effort brings together the high quality of North Kansas City Hospital with the clinical cancer program attached to the only National Cancer Institute (NCI)-designated program in our region.”
2750, Medical Plaza building
New patients seeking radiation oncology services on the Hospital campus will see Mark Thompson, MD, a radiation oncologist from The University of Kansas Cancer Center. Patients currently receiving treatment from Patrick Townsend, MD, will continue to be seen by Dr. Townsend until radiation treatments are completed.
Heartland Hematology-Oncology Associates, P.C., with physicians Venkatadri Beeki, MD, Mark DeWolfe, MD, and Jamie Rigden, MD, will continue to provide cancer care and outpatient infusion care on the Hospital’s 5th floor Oncology Unit.
NCI Clinical Trials
By partnering with The University of Kansas Cancer Center, we will continue to ensure the very best cancer care is available for patients in the Northland. Patients will now have even greater access to options only currently available at a National Cancer Institute-designated Cancer Center, including access to NCI clinical trials.
To learn more, call 816-691-3041.